WE CLAIM:

1. A dosage form comprising a pharmaceutically active compound and ~~A purified~~ 2R-dodecyl 2-(N,N-dimethylamino)-propionate or a salt thereof, wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has ~~having~~ an enantiomeric purity of at least ~~about~~ 70 %, wherein the dosage form is a cream or a gel.

2. The dosage form of claim 1 wherein the ~~purified~~ 2R-dodecyl 2-(N,N-dimethylamino)-propionate ~~of claim 1 having~~ has an enantiomeric purity of at least ~~about~~ 80 %.

3. The dosage form of claim 1 wherein the ~~purified~~ 2R-dodecyl 2-(N,N-dimethylamino)-propionate ~~of claim 1 having~~ has an enantiomeric purity of at least ~~about~~ 90 %.

4. The dosage form of claim 1 wherein the ~~purified~~ 2R-dodecyl 2-(N,N-dimethylamino)-propionate ~~of claim 1 having~~ has an enantiomeric purity of at least ~~about~~ 98 %.

~~5. A crystalline salt of the purified 2R-dodecyl 2-(N,N-dimethylamino)-propionate of claim 1.~~

5~~6~~. The dosage form ~~crystalline salt~~ of any one of claims 1-4~~5~~, ~~which is~~ wherein the salt is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acid addition salts.

6~~7~~. The dosage form ~~crystalline salt~~ of any one of claims 1-4~~5~~, ~~which is~~ wherein the salt is selected from the group consisting of acetic, benzoic, salicylic, glycolic, succinic, nicotinic, tartaric, maleic, malic, pamoic, methanesulfonic, cyclohexanesulfamic, picric, and lactic acid addition salts.

~~8. A purified 2S-dodecyl 2-(N,N-dimethylamino)-propionate having an enantiomeric purity of at least about 70 %.~~

~~9. The purified 2S-dodecyl 2-(N,N-dimethylamino)-propionate of claim 7 having an enantiomeric purity of at least about 80 %.~~

~~10. The purified 2S-dodecyl 2-(N,N-dimethylamino)-propionate of claim 7 having an enantiomeric purity of at least about 90 %.~~

~~11. The purified 2S-dodecyl 2-(N,N-dimethylamino)-propionate of claim 7 having an enantiomeric purity of at least about 98 %.~~

~~12. A crystalline salt of the purified 2R-dodecyl 2-(N,N-dimethylamino)-propionate of claim 8.~~

~~13. The crystalline salt of claim 12, which is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acid addition salts.~~

~~14. The crystalline salt of claim 12, which is selected from the group consisting of acetic, benzoic, salicylic, glycolic, succinic, nicotinic, tartaric, maleic, malic, pamoic, methanesulfonic, cyclohexanesulfamic, picric, and lactic acid addition salts.~~

7~~15~~. Use of the dosage form of any one of claims 1 to 6 in the manufacture of a medicament for ~~A method of~~ facilitating transport of a pharmaceutically active compound through a biological membrane or tissue.~~, the method comprising contacting the membrane or tissue with the pharmaceutically active compound in the presence of 2R-dodecyl 2-(N,N-dimethylamino)-propionate having an enantiomeric purity of at least about 70 %.~~

8~~16~~. The use ~~method~~ of claim 7~~15~~ wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of at least ~~about~~ 80 %.

9~~17~~. The use ~~method~~ of claim 7~~15~~ wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of at least ~~about~~ 98 %.

10~~18~~. The use ~~method~~ of any one of claims 7 to 9,~~15~~ wherein the facilitating comprises increasing the rate of oral uptake of the pharmaceutically active compound into the blood stream of a mammal after orally administering a solution of the pharmaceutically active compound and the 2R-dodecyl 2-(N,N-dimethylamino)-propionate to the mammal, as compared to the rate of uptake observed with 2S-dodecyl 2-(N,N-dimethylamino)-propionate of the same enantiomeric purity at the same dosage level.

11~~19~~. The use ~~method~~ of any one of claims 7-10,~~15~~ wherein the pharmaceutically active compound comprises lansoprazole.

12. A pharmaceutically active compound admixed with 2R-dodecyl 2-(N,N-dimethylamino)-propionate or a salt thereof wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of 70% to 98%.

13. The pharmaceutically active compound admixed with 2R-dodecyl 2-(N,N-dimethylamino)-propionate or a salt thereof of claim 12 wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of at least 80%.

14. The pharmaceutically active compound admixed with 2R-dodecyl 2-(N,N-dimethylamino)-propionate or a salt thereof of claim 12, wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of at least 90%.

15. The pharmaceutically active compound admixed with 2R-dodecyl 2-(N,N-dimethylamino)-propionate or a salt thereof of claim 12 wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of 98%.

16. The pharmaceutically active compound admixed with 2R-dodecyl 2-(N,N-dimethylamino)-propionate or a salt thereof of anyone of claims 12 to 15, which is formulated for oral administration.

17. The dosage form of any one of claims 1-6, which is a cream.

18. The dosage form of any one of claims 1-6, which is a gel.

19. A dosage form comprising a pharmaceutically active compound and 2R-dodecyl 2-(N,N dimethylamino)-propionate or a salt thereof, wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of at least 70%, wherein the dosage form is a solution formulated for oral administration.

20. A pharmaceutically active compound admixed with 2R-dodecyl 2-(N,N dimethylamino)-propionate or a salt thereof wherein the 2R-dodecyl 2-(N,N-dimethylamino)-propionate has an enantiomeric purity of at least 80%, at least 90%, or of 98%.